Moreover, G9a was found to be overexpressed in erlotinib resistant (i.e., Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistant) non-small cell lung cancer (NSCLC) cells (Table 1) (Wang L. et al., 2018). Here, EHMT2 is linked to non-small cell lung carcinoma.